ArQule-Pfizer deal breaks mold

Article Abstract:

ArQule, a biotechnology company in Medford Mass., signed a technology transfer deal with Pfizer. The deal is worth $117 million and will include the production of exclusive microarray libraries to Pfizer and make it available nonexclusively to Pfizer for another 4.5 years.

Biochemistry, Strategic alliances, Pfizer Inc., PFE, ArQule Inc.

---

Sequenom steps toward drug development

Article Abstract:

Cambridge, UK-based clinical genomics company Gemini Genomics and San Diego, CA-based genetic analysis firm Sequenom have decided to merge their businesses in a stock-for-stock deal worth $238 million.

United Kingdom, Acquisitions & mergers, Genetic Engineering, All Other Miscellaneous Ambulatory Health Care Services, Health and allied services, not elsewhere classified, Misc Medical Services, Medical care, Gemini Genomics, Sequenom Inc.

---

Chiral drugs viable, despite failure

Article Abstract:

Eli Lilly decided not to re-engineer Sepracor's Prozac, an action that is usually done to maintain a drug patent, which resulted in some financial uncertainty in Sepracor.

Product development, Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Financial analysis, Antidepressant Preparations, Eli Lilly and Co., Antidepressants, LLY, Sepracor Inc., SEPR

Similar abstracts:

• Abstracts: The value in breaking up. Drips are drying up
• Abstracts: US lessons for UK telcos. Shop till you drop. The next generation
• Abstracts: The strange death of high-yield stocks. The equity countdown may have begun. Market makers ate my hamster
• Abstracts: Alkit Digital Imaging studio caters to artists. F.J. Westcott Co. celebrates 75 years. Creativity pays off in National Photo Month promotion
• Abstracts: Dealing with technology. Teching stock of the situation. Technology on fire

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.